

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/510,674; Conf. #1884	
			Filing Date	May 23, 2005	
			First Named Inventor	Bianca Brogmann	
			Art Unit	1627	
			Examiner Name	Samira Jean-Louis	
Sheet	1	of	1	Attorney Docket Number	085742-0487

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	5549912	08/27/1996	Oshlack et al.	
	A2	5591452	01/07/1997	Miller et al.	
	A3	2005/0245483	11/03/2005	Brogmann et al.	
	A4	2005/0245556	11/03/2005	Brogmann et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	AU200205559	11/25/2002	Endo Pharmaceuticals, Inc.		
	B2	DE2138593 (and English translation)	03/30/1972	Bristol-Myers Co.		<input checked="" type="checkbox"/>
	B3	EP624366	11/17/1994	Euroceltique S.A.		
	B4	GB1353815	05/22/1974	Bristol-Myers company		
	B5	WO1996/014058	05/17/1996	Euro-Celtique, S.A.		
	B6	WO2003/073937	09/12/2003	Euro-Ceitique S.A.		
	B7	WO2003/084504	10/16/2003	Euro-Ceitique S.A.		
	B8	WO2003/084520	10/16/2003	Euro-Ceitique S.A.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	C1	Chen et al., "Oral naloxone reverses opioid-associated constipation," <i>Foreign Medical Sciences: Anaesthesiology and Resuscitation</i> , Vol. 21, No. 5, page 319 (2000).			
	C2	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability," <i>Pain</i> , Vol. 84, pp. 121-131 (2000).			
	C3	Eisenberg et al., "Buprenorphine's physical dependence potential: Antagonist-precipitated withdrawal in humans," <i>J. Pharmacol. Exp. Therapeut.</i> , Vol. 276, No. 2, page 449 (1996).			
	C4	Hexal Opposition to related application EP 1492506, dated September 30, 2009 (English translation only) (12 pages).			
	C5	Kanof et al., "Clinical characteristics of naloxone-precipitated withdrawal in human opioid-dependent subjects," <i>J. Pharmacol. Exp. Therapeut.</i> , Vol. 260, No. 1, pp. 355-363 (1992).			
	C6	Meissner et al., "A randomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation," <i>Eur. J. Pain</i> , Vol. 13, pp. 56-64 (2009).			
	C7	Mundipharma Clinical Studies Report A2-3759, "Validation of Bowel Function Index," June 15, 2005 (Rev. July 12, 2005).			
	C8	Mundipharma Clinical Studies Report OXN 2401, "Optimization of Naloxone-Oxycodone			
Examiner Signature	NYK 1361302-1.085742.0487			Date Considered	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/510,674; Conf. #1884
				Filing Date	May 23, 2005
				First Named Inventor	Bianca Brogmann
				Art Unit	1627
				Examiner Name	Samira Jean-Louis
Sheet	2	of	1	Attorney Docket Number	085742-0487

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Ration in Pain Patients," June 3, 2005.	
	C9	Muncipharma Clinical Study Results for Controlled Release of Oxycodone/Naloxone Formulations," Phase II Study (undated).	
	C10	Mundipharma's Opposition to Endo's Australian Patent Application No. AU2002305559 filed October 1, 2008 (4 pages).	
	C11	Nadstawek et al., "Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain," <i>Int. J. Clin. Pract.</i> , Vol. 62, No. 8, pp. 1159-1167 (2008).	
	C12	Vondrackova et al., "Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain," <i>Journal of Pain</i> , Vol. 9, No. 12, pp. 1144-1154 (2008).	
	C13	Zhou et al., "A clinical analysis of 18 cases of naloxone treating pruritus due to cholestia, hebei," <i>Modern Journal of Integrated Traditional Chinese and Western Medicine</i> , Vol. 8, No. 1, page 43 (1999) (English translation only).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	NYK 1361302-1.085742.0487	Date Considered	
-----------------------	---------------------------	--------------------	--